Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
Global Climate Change01:50

Global Climate Change

28.9K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
28.9K
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

509
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
509
Errors in Global Positioning System01:26

Errors in Global Positioning System

352
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
352
Global Regulatory Systems01:28

Global Regulatory Systems

667
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
667
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

327
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.6K

Larotrectinib: First Global Approval.

Lesley J Scott1

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|January 13, 2019
PubMed
Summary
This summary is machine-generated.

Larotrectinib is a targeted therapy for cancers with NTRK gene fusions. This oral medication offers a new treatment option for adult and pediatric patients with these rare genetic alterations.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Related Experiment Videos

Last Updated: Jan 30, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Larotrectinib is a small molecule inhibitor targeting tropomyosin receptor kinase (TRK).
  • Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are key drivers in certain cancers.
  • Targeted therapies offer precision medicine approaches for oncological conditions.

Purpose of the Study:

  • To summarize the development milestones of larotrectinib.
  • To highlight the regulatory approval of larotrectinib for NTRK gene fusion-positive cancers.
  • To provide an overview of larotrectinib as a treatment for specific solid tumors.

Main Methods:

  • Review of preclinical and clinical development data for larotrectinib.
  • Analysis of regulatory submissions and approvals in the USA and EU.
  • Summary of the drug's mechanism of action and target population.

Main Results:

  • Larotrectinib received its first global approval in the USA in November 2018.
  • The drug is indicated for adult and pediatric patients with NTRK gene fusion-positive solid tumors.
  • A registration application has been submitted in the EU for similar indications.

Conclusions:

  • Larotrectinib represents a significant advancement in targeted cancer therapy.
  • The drug demonstrates efficacy in patients with NTRK gene fusions, irrespective of tumor type.
  • Continued development and regulatory review are expanding access to this important treatment.